Introduction {#Sec1}
============

The liver is a key-regulator of multiple complex metabolic pathways and the hepatocyte is a primary cell type affected in numerous inherited genetic/metabolic diseases (Clayton [@CR54]). Despite a wide range of disease-specific conventional therapies, liver replacement therapies remain a valid strategy and even a potential cure for many monogenic liver disorders due to the ability to restore the defective pathway (Sokal [@CR200]). Liver replacement options include whole or partial organ (Spada et al [@CR201]), or hepatocytes transplantation (Dhawan et al [@CR68]). The shortage of donors, the associated mortality/morbidity and need for immunosuppression, however, often limit this option to severely affected patients and those aged more than 3 months or weighing greater than 5 kg (Haberle et al [@CR92]). In the past decade, liver-directed gene therapy has emerged as a promising alternative to transplantation in monogenic liver disorders.

Overview of gene therapy development: reaching maturity {#Sec2}
=======================================================

Gene therapy, by providing additional functional gene copies, has been considered for decades as an attractive option for treatment of monogenic disorders (Wirth et al [@CR226]). According to the Gartner hype cycle, a graphical representation depicting the maturity of novel technologies, gene therapy reached its "peak of inflated expectation" in the mid-1990s which was paralleled by a rapid rise in clinical trial activity and the publication of early proof-of-concept studies for genetic and acquired conditions such as adenosine-deaminase deficiency (ADA-SCID) (Blaese et al [@CR20]; Bordignon et al [@CR22]) and brain tumours, respectively (Puumalainen et al [@CR183]). This period of inflated expectation was critiqued in the Orkin-Motulsky report commissioned by the National Institute of Health (Orkin and Motulsky [@CR174]). While acknowledging the extraordinary promise of gene therapy, the report emphasised the need for greater focus on gene transfer technology and the basic science of gene transfer. Soon after, the field plunged into its "trough of disillusionment" following the death of a young adult, Jesse Gelsinger, in a clinical trial for ornithine transcarbamylase (OTC) deficiency (Raper et al [@CR189]). Optimism arising from the subsequent clinical success in the treatment of X-linked severe combined immunodeficiency (SCID-X1) (Cavazzana-Calvo et al [@CR42]) was soon dampened by the occurrence of leukaemia in five out of 20 patients secondary to insertional mutagenesis (Hacein-Bey-Abina et al, [@CR93], [@CR94]; Fischer et al [@CR78]; Mukherjee and Thrasher [@CR159]), causing the death of one participant (Mukherjee and Thrasher [@CR159]). Resultant concerns over gene therapy were further compounded by growing awareness of the challenges imposed by vector-induced immune responses (Mingozzi and High [@CR147]). Disbelief and doubt followed, leading to a decline in financial investment (Ledley et al [@CR121]). In parallel, these adverse events motivated researchers to seek a better understanding of the challenges posed by disease pathophysiology and to develop safer and more efficient vectors. Recent clinical successes in various inherited orphan diseases such as Leber's congenital amaurosis (Bainbridge et al [@CR10]; Cideciyan et al [@CR53]; Maguire et al [@CR131]), X-linked adrenoleukodystrophy (Cartier et al [@CR39]), metachromatic leukodystrophy (Biffi et al [@CR19]) and haemophilia B (Nathwani et al [@CR164]) and the first market authorisation granted by the European Medicines Agency (EMA) in 2012, to Glybera® for lipoprotein lipase deficiency (Bryant et al [@CR32]), are driving the field up the "slope of enlightenment" and onto the "plateau of productivity". As a result of this success, various biotechnology companies dedicated to gene therapy development have been created and received substantial financial investment (Cassiday [@CR40]). In parallel, the number of gene therapy-based clinical trials has risen rapidly in recent years ([http://www.abedia.com/wiley/](http://www.abedia.com/wiley)(accessed 2017 Jan 06); Ginn et al [@CR87]).

Strategies for hepatocyte-directed gene transfer {#Sec3}
================================================

A growing toolbox is available for gene transfer, which has been the preferred approach in recent human trials targeting hepatocytes. Various elements in the choice of transgene expression cassette design, mode of delivery and the subset of patients targeted influence the efficacy of gene therapy (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1The triad to consider for successful gene therapy

Parameters of vector delivery {#Sec4}
-----------------------------

The mode of transgene delivery is crucial: i) local injection allows highly selective expression, but in a limited area. Conversely an intravenous injection allows a broad distribution balanced by non-specificity. Injections in the hepatic artery or the portal vein improve the selectivity but require cannulation with its associated risks (Fumoto et al [@CR82]). Peripheral intravenous delivery provides similar transduction compared to intrahepatic or intraportal routes for AAV vectors (Sarkar et al [@CR194]; Nathwani et al [@CR163]); ii) higher doses of vector achieve greater transduction, but may generate more severe immune responses (Raper et al [@CR189]; Mingozzi and High [@CR149]).

Host pre-sensitisation or acquired immune responses {#Sec5}
---------------------------------------------------

The immune response against the vector and/or the transgene product might preclude the expected therapeutic effect (Jooss and Chirmule [@CR106]; Zaiss and Muruve [@CR235]; Wold and Toth [@CR227]).

Immune memory of pre-exposure to wild-type viruses can prevent efficient hepatocyte transduction by pre-existing neutralising antibodies and might account for differences in the severity of immune responses observed after systemic injection. Pre-immunisation against the transgene product can occur when the recombinant transgenic protein has been administered. For example, in haemophilia B patients, this can result in the generation of anti-factor IX antibodies when treated by recombinant factor IX (Armstrong et al [@CR6]). Accordingly prior immunisation needs to be carefully considered in clinical trial enrolment criteria.

Acquired immune responses after systemic gene delivery are common. Innate immune responses are triggered by antigen presenting cells such as dendritic cells or macrophages initiating the release of proinflammatory cytokines (interleukins 1 and 6, tumour necrosis factor α (TNFα), type I interferon α and β) via stimulation of Toll-like receptors (TLR). Specific and long-lasting antigen-specific immune responses are mediated by B- and T-cells and involve secretion of neutralising antibodies and CD8^+^ cytotoxic T lymphocytes, respectively, regulated by the recruitment of helper and regulatory CD4^+^ T cells. Whatever the viral vector considered, immune responses share various similarities, and must always be carefully considered (Bessis et al [@CR18]; Tang et al [@CR208]; Annoni et al [@CR4]; Calcedo and Wilson [@CR35]; Basner-Tschakarjan and Mingozzi [@CR12]).

Design and selection of the gene transfer vector {#Sec6}
------------------------------------------------

The *transgene expression cassette* contains i) a transgene, which is commonly a cDNA and may be codon-optimised to achieve higher expression of the transgene product, ii) an enhancer/promoter, the selection of which determines the level of transgene expression, cell-type restricted specificity of expression and also influences the risk of insertional mutagenesis, iii) various pre- and/or post-regulatory elements to stabilise transgene mRNA and therefore increase the yield of transgene product, e.g. addition of an intron downstream of the promoter containing a bacterial replication origin (Lu et al [@CR129]) or the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) (Lipshutz et al [@CR124]), respectively.

Several options are available to deliver the *transgene expression cassette* to the target cell/organ {#Sec7}
=====================================================================================================

Injection of *naked DNA,* either as *plasmids* (Doenecke et al [@CR69]; Oishi et al [@CR173]) or *mini-circles* (Viecelli et al [@CR219]; Hou et al [@CR101]; Wu et al [@CR229]), is a simple mode of transgene delivery which lends itself to local delivery and is relatively non-immunogenic compared to some viral vector approaches (Wolff and Budker [@CR228]). Mini-circles are devoid of plasmid backbone DNA; this may enhance transgene expression by overcoming heterochromatin formation and avoiding inflammation triggered by bacterial DNA (Mayrhofer et al [@CR137]). These approaches allow easy production of therapeutic material with a good safety profile and capable of eliciting long-lasting transgene expression in post-mitotic tissues (Wolff and Budker [@CR228]; Kay et al [@CR113]). These approaches have been employed in ∼17% of gene therapy trials so far ([http://www.abedia.com/wiley/](http://www.abedia.com/wiley)(accessed 2017 Jan 06)). The hydrodynamic injection technique, developed in small animal models, consists of injecting DNA plasmids or mini-circles in a large vehicle volume to flood the liver with pressurised DNA solution; this disrupts vascular endothelium, and allows high levels of transgene expression in small or large animal models (Liu et al [@CR126]). Although hydrodynamic injections are difficult to translate to humans, intravascular hydrodynamic procedures with partial catheterisation for liver-directed gene delivery have shown some success in large animals (Sendra et al [@CR198]; Yokoo et al [@CR234]). However, current translatable options of non-viral approaches remain limited. Therefore viral vectors, acting as Trojan horses to increase transduction efficiency, are frequently considered.

*Non-viral vectors* are synthetically produced biological particles, in which the transgene is encapsulated, or complexed, and released at the target site. Various engineered nanoparticles exist, e.g. liposomes or/and polymers (Chira et al [@CR50]). These options have several advantages: easy production, no restriction of the transgene size, and a reliable safety profile. Limitations are the stability of these particles, cellular uptake and a limited ability to achieve long-lasting transgene expression (Elsabahy et al [@CR76]). These are therefore suboptimal delivery vehicles for liver-directed clinical trials.

*Virus-derived vectors* represent an attractive approach based on their relatively efficient transduction human cells. The main vectors that have been used in clinical trials are derived from adenoviruses (21%), retroviruses (excluding lentiviruses) (19%), adeno-associated viruses (7%) and lentiviruses (6%) ([http://www.abedia.com/wiley/](http://www.abedia.com/wiley)(accessed 2017 Jan 06)).

Retroviral vectors {#Sec8}
==================

*Gamma-retroviruses* such as murine leukaemia viruses (MLVs) are RNA viruses encoding *gag*, *pol* and *env* genes flanked by long terminal repeats (LTRs), which carry enhancers/promoter elements and are required for integration. After transduction of the target cell, reverse-transcription generates a double-stranded DNA copy of the proviral genome, which then integrates in the host genome providing long-term transgene expression. Gamma-retroviruses are unable to transduce non-dividing cells as the nuclear membrane prevents retroviral vectors from entering the nucleus (Miller et al [@CR146]). This explains why this vector is more often considered for ex vivo gene therapy in which cultured target cells are stimulated to replicate and then transduce. *Lentiviruses* are a class of retroviruses, the most widely known of which is HIV1. Lentiviral vectors are able to transduce dividing and non-dividing cells, which broadens their application. Retroviral vectors have relatively large transgene capacities (7.5 kilobases (kb)) (Verma and Somia [@CR218]). In fact payloads exceeding 14 kilobases have been packaged into lentiviral vectors (Counsell et al, [@CR60]).

*Clinical applications and limitations:* In an early gene therapy trial, a γ-retroviral vector was used in an ex vivo approach with autologous hepatocytes in five patients with homozygous familial hypercholesterolemia. This showed a mild improvement of lipid profiles in two patients with a very low rate of stable engraftment at 4 months after gene therapy (Grossman et al [@CR90]; Grossman et al [@CR91]). Several limitations emerged from this trial: i) the need for two invasive procedures, i.e. the surgical resection of a liver lobe to obtain sufficient primary hepatocytes for transduction as hepatocytes cannot be expanded in culture and reinjection of transduced hepatocytes into the portal circulation via a local catheter, with the associated risks of venous thrombosis, catheter misplacement and haemorrhage (Grossman et al [@CR90]; Raper et al [@CR186]). The efficiency with which hepatocytes were harvested and transduced was low, 30% and 10% respectively (Grossman et al [@CR91]). Protocols for lentiviral-mediated gene therapy have improved with in vitro transduction efficacy reaching 90% in non-human and human hepatocytes (Nguyen et al [@CR168]). Hepatocyte transplantation, however, remains relatively inefficient and variable, likely due to poor engraftment, limited persistence of engrafted hepatocytes and the lack of a proliferative advantage (Gramignoli et al [@CR88]).

Retroviral-mediated in vivo gene therapy was well tolerated when vector was administered intravenously in haemophilia A patients, but no significant clinical benefits were observed (Powell et al [@CR182]). Preclinical studies failed to accurately predict the therapeutic dose and it was suggested that retroviral vectors were unable to transduce non-dividing hepatocytes (Chuah et al [@CR52]). Therefore, alternative viral vectors, including lentiviral vectors, have been developed for treatment of hemophilias. Indeed two promising approaches with lentiviral vectors are in preclinical development: i) systemic lentiviral-mediated liver-restricted gene therapy in a dog model of haemophilia B, which showed long-term efficacy, induction of liver tolerogenic properties in stimulating CD4^+^CD25^+^FoxP3^+^ regulatory T cells and no evidence of genotoxicity in mice (Cantore et al [@CR38]). The immune tolerance is of particular interest for patients with anti-FIX inhibitors, who are currently excluded from gene therapy trials; ii) ex vivo transduction of haematopoietic stem cells (HSC) in mice with successful *FIX* gene expression to target cells of the erythroid (Chang et al [@CR47]) or the megakaryocyte lineage (Chen et al [@CR48]). A lentiviral vector is currently in preclinical development for haemophilia B (Dolgin [@CR70]). Lentiviral vectors are able to accommodate large transgenes such as *FVIII* gene for haemophilia A (Kuether et al [@CR120]). Lentiviral-mediated liver-directed ex vivo gene therapy has been successfully reported in a pig model of tyrosinaemia 1 using the selective advantage of *Fah* ^*+/+*^ modified hepatocytes (Hickey et al [@CR98]).

The risk of insertional mutagenesis has been reported with retroviral vectors (Cavazzana-Calvo et al [@CR42]; Mukherjee and Thrasher [@CR159]), however, there is evidence that the risk is lower with lentiviral vectors (Kotterman et al [@CR119]). To improve safety, self-inactivating (SIN) vectors have been developed in which LTR enhancer/promoter elements in the U3 region have been deleted (Miyoshi et al [@CR153]; Zufferey et al [@CR238]). This, however, does not completely eliminate the risk of insertional mutagenesis as heterologous enhancer-promoter elements still need to be included in vector constructs. Genotoxicity has been observed after foetal injections of non-primate and primate SIN-lentiviral vectors (Nowrouzi et al [@CR172]; Condiotti et al [@CR56]). So far, more than 125 patients over 14 years have been treated with haematopoietic stem cells or T cells transduced by lentiviral vectors with no oncogenic event reported (Cartier et al [@CR39]; Biffi et al [@CR19]; McGarrity et al [@CR141]; Booth et al [@CR21]). Another approach relies on the mutation of the integrase protein to generate non-integrating or integration-deficient lentiviral vectors (Nightingale et al [@CR170]; Philippe et al [@CR178]; Yanez-Munoz et al [@CR231]), which have shown long-lasting gene expression in non-dividing tissues (Apolonia et al [@CR5]; Rahim et al [@CR185]) and phenotype correction in mice with haemophilia B (Suwanmanee et al [@CR205]).

Adenoviral vectors {#Sec9}
==================

*Adenoviruses* are non-enveloped double-stranded DNA viruses with a large 36 kb genome and are capable of transducing dividing and non-dividing cells. In humans, a common target is epithelial cells of the respiratory or gastrointestinal tracts causing mild upper respiratory tract infection, gastroenteritis, or asymptomatic seroconversion. More than 55 serotypes are described but most vectors are derived from endemic serotypes 2 and 5 (Piccolo and Brunetti-Pierri [@CR179]). The seroprevalence against the most common serotype (Adenovirus 5) is high with neutralising antibodies in 45--80% (Kotterman et al [@CR119]). Adenoviruses elicit a sustained innate and cytotoxic-mediated immunity, which leads to the clearance of transduced cells (Tang et al [@CR208]; Thaci et al [@CR209]). Neither adenoviruses nor adenoviral vectors have been associated with genotoxicity in humans (Stephen et al [@CR202]). Adenoviral vectors can accommodate large transgenes, which remain episomal in the transduced cell but enable a long-lasting transgene expression in quiescent or dividing cells. In animal models, adenoviral vectors exhibit strong liver tropism through interaction with coagulation factor X (Kalyuzhniy et al [@CR109]; Vigant et al [@CR220]; Waddington et al [@CR221]).

Clinical applications and limitations {#Sec10}
-------------------------------------

In adenoviruses, expression of genes occurs in two early and late phases. The early phase is mediated by E1-E4 transcription units. Proteins encoded by E1 are essential for viral gene expression and DNA replication. Late gene expression is mediated by an internal promoter (Benihoud et al [@CR15]). First-generation adenoviral vectors have E1 or E1-E3 regions removed and are theoretically replication-defective. However, these vectors keep a mild "leaky" expression of viral genes and are still able to synthesise some viral proteins, likely due to E1-like protein in the target cells (Zhang et al [@CR236]; Lozier et al [@CR128]). Moreover, the immunogenic properties of first-generation adenoviral vectors cause severe acute innate and chronic adaptive immune responses in small and large animal models (Yang et al [@CR232]). To reduce this immune response, deletion of transcription units E1/E2/E3, E1/E4/E3, E1/E2/E3/E4) has been introduced (Alba et al [@CR1]). Only the last combination achieved a reduction of vector toxicity, but with a reduced duration of the transgene expression (Gao et al [@CR83]; Raper et al [@CR187]; Andrews et al [@CR2]). A second generation (E1- and E4- deleted) adenoviral 5 vector was used for the OTC deficiency trial, in which Jesse Gelsinger, a young adult with late-onset OTC deficiency enrolled in the highest dose group, died after developing a fatal acute toxic reaction with fulminant inflammatory response and multi-organ failure hours after the injection of the vector (Raper et al [@CR189]). It has been hypothesised that this was caused by an innate immune response with a cytokine storm triggered by antigen presenting cells against capsid proteins (Raper et al [@CR189]). The reason for severity of this immune response remains unclear as another patient injected with the same dose exhibited only mild flu-like symptoms. A genetic predisposition or an immune memory response caused by pre-exposure to adenoviruses might partly explain this discrepancy (Wilson [@CR224]). In this trial, safety issues were surprisingly not dose-related and had not been predicted to this extent by animal studies (Raper et al [@CR188]). Furthermore, no significant clinical benefit was observed (Raper et al [@CR188]).

To limit this immune response, "gutless" or helper-dependent adenoviral vectors (HD-Ad) have been designed by deletion of all coding regions except the ITRs and the packaging signal (Ψ) required for the encapsidation of the adenoviral genome, which have been replaced by the transgene cassette and stuffer DNA (Alba et al [@CR1]). This new generation of vectors have shown an improved safety profile, exhibiting a reduced acute innate immune response and an absence of chronic toxicity. In first-generation adenoviral vectors, the "leaky" expression of the remaining viral genes have a direct cytotoxic effect and triggers an adaptive cellular immune response directed against the transduced cell, which in turn results in transient transgene expression and chronic toxicity (Brunetti-Pierri and Ng [@CR28]). As HD-Ad do not contain any viral genes, this late toxicity is not observed, which allows a long-term transgene expression as observed in small (Kim et al [@CR115]; Toietta et al [@CR211]) and large animal models (Morral et al [@CR157]; Brunetti-Pierri et al [@CR31]). This has allowed successful long-term phenotypic correction of various liver monogenic disorders (Brunetti-Pierri and Ng [@CR28]), among which haemophilia A (Reddy et al [@CR191]; Hu et al [@CR102]), haemophilia B (Ehrhardt and Kay [@CR74]), OTC deficiency (Mian and Lee [@CR144]), glycogen storage disease 1A (Koeberl et al [@CR116]), Criggler-Najjar syndrome (Schmitt et al [@CR197]), primary hyperoxaluria type 1 (Castello et al [@CR41]), acute intermittent porphyria (Unzu et al [@CR216]), phenylketonuria (Cerreto et al [@CR43]), familial hypercholesterolaemia caused by mutations in the *LDLR* (Nomura et al [@CR171]) and *ApoE* genes (Belalcazar et al [@CR13]) in rodents, haemophilia A (Brown et al [@CR27]; McCormack et al [@CR140]) and B (Ehrhardt et al [@CR75]; Brunetti-Pierri et al [@CR30]), glycogen storage disease type 1 (Crane et al [@CR62]) in dogs, and haemophilia A and B and Pompe disease (Rastall et al [@CR190]) in non human primates.

However, the acute innate immune response directed against capsid proteins is not abolished in HD-Ad vectors (Muruve et al [@CR161]). For both first-generation and helper-dependent adenoviral vectors, this acute immune response is dose-dependent and can be lethal at high doses in non human primates (Morral et al [@CR158]; Brunetti-Pierri et al [@CR29]). Differences in the severity of the immune response between species have emerged due to variable interactions between blood cells and hepatic microarchitecture such as size of liver sinusoidal fenestration (Piccolo and Brunetti-Pierri [@CR179]). The activation of this innate immunity is multifactorial. Adenoviral particles can trigger the immune response by binding to Toll-like receptors (TLR2, TLR9) at the surface of antigen presenting cells, and/or activate the complement cascade in the bloodstream (Kiang et al [@CR114]; Zhu et al [@CR237]). Kupffer cells recognise the adenoviral capsid either via antibody-mediated opsonisation or in binding complement factors. Kupffer cells develop a pro-inflammatory state with necrotic death, which further disseminate the immune response (Schiedner et al [@CR195]).

In vivo HD-Ad mediated gene therapy has been performed in one patient in a phase I trial for haemophilia A. After a single intravenous low-dose injection, the patient developed flu-like symptoms with transient fever, chills, back pain, headache and transient biological abnormalities including thrombocytopenia, laboratory features of disseminated intravascular coagulopathy, increase in interleukin 6 levels, and elevated liver transaminase levels peaking at 7 days (marked as grade 3 liver toxicity) (Chuah et al [@CR52]; White and Monahan [@CR223]; Chandler and Venditti [@CR44]). The patient expressed 1% FVIII for some months but the trial was halted for safety reason although biological abnormalities came back to normal within 19 days. Unfortunately, this trial has not been published in a peer-reviewed format and few details are available (Piccolo and Brunetti-Pierri [@CR179]). The cause of these symptoms remains unclear although, as supposed for the OTC trial involving Jesse Gelsinger, the innate immune response against the adenoviral capsid and its subsequent release of cytokines has been suspected (Chuah et al [@CR52]). Contamination by an adenoviral helper virus remains a possible explanation (Chuah et al [@CR52]).

Despite limited application for liver monogenic disorders, adenoviral vectors have been successfully used for oncolytic virotherapy (Rosewell Shaw and Suzuki [@CR192]) and vaccination (Majhen et al [@CR133]), which exploits adenoviral immunogenicity.

Adeno-associated viral vectors {#Sec11}
==============================

*Adeno-associated viruses* (AAV) are non-enveloped, single-stranded DNA viruses that belong to the *Dependovirus* genus and the *Parvoviridae* family. Initially identified as a contaminant of an adenoviral preparation (Atchison et al [@CR8]), the virus was later shown to require co-infection with a helper virus to replicate. In the absence of helper virus, AAV can enter target cells and establish latent infection through genomic integration and/or formation of episomes. AAV is widely considered non-pathogenic and has yet to be definitively linked to disease causation. AAVs can transduce dividing and non-dividing cells. The seroprevalence against the most common serotype AAV2 is 40--60% (Louis Jeune et al [@CR127]). AAV virions consist of an icosahedral capsid of approximately 22 nm in diameter enclosing a 4.7 kb single-stranded genome. The genome is flanked by two 145 nucleotide inverted terminal repeats (ITRs) containing all of the necessary *cis*-acting functions for proviral rescue, genome replication and packaging. The viral genome encodes 4 Rep proteins required for proviral rescue and genome replication, and three viral proteins VP1, VP2 and VP3, which assemble to form the capsid (Fig. [2](#Fig2){ref-type="fig"}A) (Samulski and Muzyczka [@CR193]). Some, but not all, AAV capsid serotypes (Earley et al [@CR73]) require expression of an assembly-activating protein (AAP) encoded by an alternative reading frame of the *Cap* gene and providing scaffolding activity (Naumer et al [@CR167]). Numerous AAV serotypes have been isolated from humans, non-human primates and other species, with the viral capsid determining species and target cell tropism through interaction with a diversity of cell surface receptors/co-receptors and intracellular trafficking pathways that remain incompletely understood. A multi-serotype AAV receptor has been recently identified (Pillay et al [@CR181]), but its precise role in uptake and trafficking has yet to be elucidated (Summerford and Samulski [@CR203]). For example, AAV3B uses the human hepatocyte growth factor (hHGF) receptor, which restricts transduction to primates and especially to the liver (Vercauteren et al [@CR217]).Fig. 2Synthesis of an AAV vector. **(a)** Initially, the single-stranded proviral DNA is excised to remove *Rep* and *Cap* genes from different wild type AAV serotypes. The transgene expression cassette containing the promoter, the transgene and various regulatory elements is cloned between the 2 ITRs, which are the only wild type AAV sequences retained. (**b**) For vector synthesis, triple transfection of three plasmids is performed in a packaging cell with proviral plasmid encoding the recombinant viral genome, a plasmid containing Rep and Cap and a helper plasmid. "Pseudotyped" AAV vectors contain ITRs from a specific AAV serotype (usually AAV2) and a *Cap* gene encoding viral proteins (VP1, 2 and 3) from a different serotype (*e.g* AAV8) in order to provide organ-specific transduction of the recombinant AAV vector named AAV2/8. AAV: adeno-associated virus; Adv: adenovirus; ITR: inverted terminal repeat

Since 2004, *AAV vectors* have emerged as the leading candidates for gene therapy in monogenic liver disorders with the best accepted benefit-risk ratio (Dolgin [@CR70]). Therefore, the following sections focus on this gene transfer approach detailing clinical successes and current limitations.

AAV2 is the most widely studied serotype and was the first to be vectorized. To generate a recombinant AAV vector the native *Rep* and *Cap* genes are removed and replaced by a transgene expression cassette with only the flanking ITRs retained (Fig. [2](#Fig2){ref-type="fig"}A). Recombinant virus is produced by supplying *Rep* and *Cap* and necessary adenoviral helper functions in *trans*. A major development in AAV vector technology was the demonstration that recombinant AAV2 genomes can be cross-packaged, or pseudo-serotyped, with the capsids from other AAV serotypes (Rabinowitz et al [@CR184]). This has dramatically broadened the cell types that can be efficiently targeted with AAV vectors. For example, pseudo-serotyping a recombinant AAV2 vector genome with the AAV8 capsid (designated AAV2/8) enhances tropism for hepatocytes, particularly in the mouse (Fig. [2](#Fig2){ref-type="fig"}B). AAV vectors bind to target cells via specific receptors and co-receptors that differ in a capsid-dependent manner and are taken up by endocytosis or macropinocytosis, before being trafficked to the nucleus for capsid uncoating. The uncoated genomes can remain in the nucleus in single-stranded form, be converted to double-stranded episomes or undergo genomic integration (Fig. [3](#Fig3){ref-type="fig"}) (Berry and Asokan [@CR17]). Conversion of input single-stranded genomes to double-stranded transcriptionally active forms occurs with variable efficiency in different cell types. Self-complementary (*sc*) vectors differ from single-stranded vectors (*ss*) in that they contain a self-complementary transgene cassette that folds back on itself to form double-stranded DNA thereby bypassing the requirement for second strand synthesis, which is considered as a rate-limiting step for transgene expression. As a consequence the packaging size of the transgene cassette in *sc*AAV is reduced by half (McCarty [@CR138]).Fig. 3AAV vector uptake, in-cell processing and initiation of the immune response. Fenestrated endothelium of hepatic sinusoids allows the AAV vector to freely reach the hepatocyte. Once reaching the target cell, the vector binds an extracellular receptor and co-receptor specific to the capsid motifs. After an uptake by endocytosis, the vector is trafficked in the cytoplasm in early then late endosome. Acidification of the endosome modifies the capsid conformation. After endosomal escape, the AAV vector enters the nucleus via the nuclear pore complex. Capsid uncoating and release of the proviral DNA precede the synthesis of the 2nd strand of DNA. The viral genome then persists either as a non-integrated single- or double-stranded episome (99%) or (small percentage) integrates into the host genome (1%). Expression of the transgene is followed by synthesis of the protein of interest. Cell-mediated immune responses are initiated by the degradation of capsid or the transgene product (protein) in the proteasome and presentation at the surface of the transduced cell via the major histocompatibility complex I. CD8^+^ T cells recognise the antigen at the cell surface and initiate the immune cascade. Neutralising antibodies bind to the vector in the bloodstream and impair or prevent successful transduction of the organ target. MHC1: major histocompatibility complex I

Clinical successes of liver-directed AAV-mediated gene therapy {#Sec12}
==============================================================

A rapidly increasing number of publications have reported proof-of-concept for AAV-based gene therapy in animal models for various inherited liver disorders including urea cycle defects, organic acidurias, phenylketonuria, glycogen storage disease type Ia, long chain fatty acid oxidation disorders, homozygous familial hypercholesterolemia, primary hyperoxaluria type I and progressive familial intrahepatic cholestasis (Hastie and Samulski [@CR95]; Junge et al [@CR107]).

In parallel, pioneering trials have been conducted since the 2000s, two of which targeted haemophilia B. This disease is an attractive target for gene therapy as an increase in plasma factor IX (FIX) of as little as 1% can confer significant phenotypic improvement. Haemophilia B is a burden in public healthcare systems with an annual cost of \$300,000 for severely affected patients (Angelis et al [@CR3]).

In 2004, a *ss*AAV2.ApoE/hAAT.*hFIX* vector, administered via the hepatic artery, showed a transient increase of plasma FIX from \<1% to 3--11% over 4 weeks followed by a gradual decline over 4--8 weeks concomitant with transient asymptomatic rise in transaminases levels (Manno et al [@CR135]), later recognised as T cell-mediated cytotoxicity (Mingozzi et al [@CR150]).

In 2009, Nathwani et al, injected a *sc*AAV2/8.LP1.*hcoFIX* vector via a peripheral intravenous route and elicited a long-lasting (\>5 years) increase of plasma FIX from \<1% to 1--8% (Nienhuis et al [@CR169]). Elevated transaminases occurring 7--10 weeks post-injection resolved after an oral course of corticosteroids, but were associated with a decrease of 50--70% in plasma FIX levels attributable to a cellular immune response against capsid epitopes (Nathwani et al [@CR165]).

D'Avola et al, recently reported results of a trial of *sc*AAV2/5.hAAT.*hcoPBGD* vector in acute intermittent porphyria with peripheral intravenous delivery. No vector-related safety issues were reported and the rate of disease-related hospitalisation decreased, potentially as a consequence of closer metabolic follow-up. No change was observed in the levels of metabolic biomarkers (D'Avola et al [@CR66]). This might be explained by a less efficient liver transduction mediated by AAV5 relative to AAV8 and a reduced expression of the episomal transgene compared to the endogenous gene of interest (Baruteau et al [@CR11]). However, no liver biopsy data was available to address this assumption.

Preliminary reports from ongoing clinical trials have confirmed Nathwani's promising results for haemophilia B. After a single intravenous injection of AAV vectors with different capsids encoding the FIX gene or its Padua FIX variant, which contains a gain-of-function mutation, reported stabilised plasma FIX levels have ranged from 3 to 8% in the AMT-060 trial sponsored by Uniqure (Miesbach et al [@CR145]) and the DTX-101 sponsored by Dimension Therapeutics (<http://dimensiontx.com>) to 20--44% in the high-dose cohort of the BAX 335 trial sponsored by Shire (Monahan et al [@CR155]) and in the SPK-9001 trial sponsored by Spark Therapeutics/Pfizer (George et al [@CR85]). In a haemophilia A gene therapy trial, BioMarin reported plasma factor VIII (FVIII) from 4 to 60% in the high-dose group of the BMN 270 trial (Pasi et al [@CR176]) (Table [1](#Tab1){ref-type="table"}). Importantly, endogenous FVIII is primarily secreted by endothelial cells (Fahs et al [@CR77]). All the AAV-based trials have so far involved only adult patients, who had an undetectable baseline titre of neutralising antibodies to the capsid (usually accepted cut-off of 1/5 serum dilution). Monogenic liver disorders in AAV-based gene therapy development pipelines of pharmaceutical companies include OTCD, glycogen storage disease type Ia, citrullinemia type I, phenylketonuria, Wilson disease, methylmalonic acideamia and Crigler-Najjar syndrome (Kattenhorn et al [@CR110]).Table 1Clinical trials of gene therapy products for liver monogenic disorders. Intraportal and intrahepatic routes of administration relate to injection on the portal vein and the hepatic artery respectively. FVIII: factor VIII; FIX: factor IX; HD-adenovirus: helper-dependent adenovirus; LDL: low density lipoprotein; MoML: Moloney murine leukaemia virus; NA: not applicable; OTC: ornithine transcarbamylase; PBGD: porphobilinogen deaminase. Information sources: [*clinicaltrial.gov*](http://clinicaltrial.gov) (accessed 06/01/2017) and company websites. If the date of the start of the trial was not available in [*clinicaltrials.gov*](http://clinicaltrials.gov) website, the date of publication of the results is mentioned. The list of trials announced for 2017 is indicative and does not pretend to be exhaustiveYear (start of trial)Viral vectorDiseaseProductTherapeuticSponsorRouteDoseNumber of treated patientsStatusReference[Clinicaltrial.gov](http://clinicaltrial.gov) identifier1992MoMLV Retrovirus 5Homozygous familial hypercholesterolaemiaNALDL receptor geneUniversity of Michigan Ann ArbourIntraportal (Ex vivo approach)1 to 3.3 × 10e9 hepatocytes5TerminatedGrossman et al [@CR90]\
Grossman et al [@CR91]\
Raper et al [@CR186]NCT000048091998Adenovirus 5Ornithine transcarbamylase deficiencyNAOTC geneUniversity of PennsylvaniaIntrahepatic2 × 10e9 to 6 × 10e11vg/kg18TerminatedRaper et al [@CR189]NCT000044981999AAV2Haemophilia BNAFactor IX geneNAIntramuscular2 × 10e11 to 1.8 × 10e12vg/kg8TerminatedKay et al [@CR112]\
Manno et al [@CR134]NA2003MoMLV RetrovirusHaemophilia ANAFVIII geneChironIntravenous2.8 × 10e7 to 4.4 × 10e8vg/kg13TerminatedPowell et al [@CR182]NA2004HD-AdenovirusHaemophilia ANAFVIII geneGenStarIntravenous4.3 × 10e10vg/kg1TerminatedChuah et al [@CR52]NA2004AAV2α1-antitrypsinNAhAAtUniversity MassachussetsIntramuscular2.1 × 10e12 to 6.9 × 10e13vg12TerminatedFlotte et al [@CR80]\
Brantly et al [@CR24]NCT003774162004AAV2Haemophilia BNAFactor IX geneAvigenIntrahepatic8 × 10e10 to 2 × 10e12vg/kg7TerminatedManno et al [@CR135]NCT000765572006AAV1α1-antitrypsinNAhAATUniversity MassachussetsIntramuscular6.9 × 10e12 to 6 × 10e13vg9TerminatedBrantly et al [@CR25]NCT004307682009AAV2/8Haemophilia BNAFactor IX geneSt Jude Children's HospitalIntravenous2 × 10e11 to 2 × 10e12vg/kg10RecruitingNathwani et al [@CR165]NCT009792382010AAV1α1-antitrypsinNAhAATApplied Genetic TechnologiesIntramuscular6 × 10e12 to 6 × 10e12vg/kg9TerminatedFlotte et al [@CR81]NCT010543392012AAV2/8Haemophilia BBAX 335Padua mutant factor IX geneShireIntravenous2 × 10e11 to 3 × 10e12vg/kg6TerminatedMonahan et al [@CR155]NCT016876082014AAV2/5Acute intermittent porphyriaNAPBGD geneDigna BiotechIntravenous5 × 10e11 to 1.8 × 10e13vg/kg8TerminatedD'Avola et al [@CR66]NCT020828602015Engineered AAVHaemophilia BSPK-9001Padua mutant factor IX geneSpark TherapeuticsIntravenous5 × 10e11 vg/kg (Low dose)7RecruitingGeorge et al [@CR85]NCT02484092AAV2/5Haemophilia BAMT-060Factor IX geneUniqure BiopharmaIntravenous5 × 10e12 to 2 × 10e13vg/kg5RecruitingMiesbach et al [@CR145]NCT02396342AAV2/rh10Haemophilia BDTX101Factor IX geneDimension TherapeuticsIntravenous1.6 × 10e12 to 1 × 10e13vg/kgUndisclosedRecruiting[clinicaltrials.gov](http://clinicaltrials.gov)NCT02618915AAV2/5Haemophilia ABMN 270Factor VIII geneBioMarin PharmaceuticalsIntravenous6 × 10e12 to 6 × 10e13vg/kg9RecruitingPasi et al [@CR176]NCT025767952016AAV2/6Haemophilia BSB-FIXFactor IX integrating in the albumin locus via Zinc-finger-nucleaseSangamo BioscinesIntravenouscDNA 4 × 10e12 to 4 × 10e13vg/kg and ZFN 5 × 10e11 to 5 × 10e12vg/kgUndisclosedRecruiting[clinicaltrials.gov](http://clinicaltrials.gov)NCT02695160AAV2/8Homozygous familial hypercholesterolaemiaRGX-501LDL receptor geneUniversity of Pennsylvania/RegenxbioIntravenous2.5 × 10e12 to 7.5 × 10e12vg/kgUndisclosedRecruiting[clinicaltrials.gov](http://clinicaltrials.gov)NCT02651675Announced for 2017AAV2/8Ornithine transcarbamylase deficiencyDTX301OTC geneDimension TherapeuticsIntravenous2 × 10e12 to 2 × 10e13vg/kgUndisclosedRecruiting[clinicaltrials.gov](http://clinicaltrials.gov)NCT02991144Engineered AAVHaemophilia ASPK-8011Factor VIII geneSpark TherapeuticsIntravenousUndisclosedUndisclosedRecruiting[clinicaltrials.gov](http://clinicaltrials.gov)NCT03003533AAV2/8Haemophilia AGO-8Factor VIII geneUniversity College LondonIntravenous6 × 10e11 to 6 × 10e12vg/kgNANot yet recruiting[clinicaltrials.gov](http://clinicaltrials.gov)NCT03001830Engineered AAVHaemophilia BFLT-180UndisclosedFreeline TherapeuticsAAV2/8Haemophilia ABAX-888Factor VIII geneShireAVVHaemophilia ADTX201Factor VIII geneDimension Therapeutics/BayerAAV2/6Haemophilia ASB-525Factor VIII integrating in the albumin locus via Zinc-finger-nucleaseSangamo BiosciencesAAV2/8Mucopolysaccharidosis VIMeuSIXARSB geneNAAAV2/8Crigler NajjarAT342UGT1A1 geneAudentes Therapeutics

Current challenges {#Sec13}
==================

Insertional mutagenesis {#Sec14}
-----------------------

Despite more than 170 AAV-based human trials approved, ongoing or completed ([http://www.abedia.com/wiley/](http://www.abedia.com/wiley)(accessed 2017 Jan 06)), no tumorigenic events have been reported so far. AAV vector genome mainly persists as episome in the transduced cell with a relatively low proportion of vector genomes undergoing integration preferentially in transcriptionally active genes, damaged DNA or enriched CpG islands (McCarty et al [@CR139]). Experiments in neonatal mice have identified an increased risk of hepatocellular carcinoma (HCC) after systemic injection. This risk increased with the enhancer/promoter activity, younger age at time of injection and vector dose (Donsante et al [@CR71]; Chandler et al [@CR45]; Chandler et al [@CR46]). Analysis of integration sites identified a rodent-specific hotspot in the *Rian* locus. Integration studies from human trials have not shown such hotspots, but rather a genome wide integration pattern involving neither HCC-related genes nor the human *Rian* homologue, *Dlk1-Dio3* (Kaeppel et al [@CR108]; Gil-Farina and Schmidt [@CR86]).

Controversies remain regarding the possible insertional mutagenic effects of wild type AAV. Detection of a clonal expansion of wild type AAV2 sequences in 11/193 HCCs within HCC-related genes (Nault et al [@CR166]) initiated a passionate and unresolved debate about "driver" or "passenger" cancer-related genetic modifications (Berns et al [@CR16]; Buning and Schmidt [@CR34]). The cumulative safety experience with the rapidly growing number of AAV-based trials targeting the human liver, combined with the low rate of HCC-associated AAV integrations despite the high seroprevalence of wild type AAV in the human population (e.g. \>50% for AAV2) (Thwaite et al [@CR210]) are consistent with a favourable safety profile of AAV vectors. Nevertheless the findings of Nault et al warrant further studies and mandate close monitoring in ongoing human trials.

Immune response {#Sec15}
---------------

After vector delivery, non-specific innate immunity triggers both type I interferon signalling involved in transgene silencing (Suzuki et al [@CR207]) and the release of proinflammatory cytokines (Jayandharan et al [@CR103]). Highly-specific and long-lasting adaptive immunity generates B- and T-cell responses against the capsid and/or the transgene product (Fig. [3](#Fig3){ref-type="fig"}). Neutralising antibodies against the capsid, even at low titers, inhibit transduction after systemic delivery (Jiang et al, [@CR104], [@CR105]). This barrier is of substantial concern to gene therapy development and the ongoing liver-directed trials are recruiting only seronegative patients without neutralising antibodies against the AAV capsid. This narrows the target population as the seroprevalence against liver-specific AAV serotypes ranges from 20 to 30% for AAV5, 6 and 8 to 50--60% for AAV2 (Louis Jeune et al [@CR127]). Cross-reactivity between serotypes is commonly \>50% (Boutin et al [@CR23]). This seroprevalence varies depending on geographic origin (Calcedo et al [@CR36]) and age. Neonates receive maternal antibodies by transplacental transfer and acquired with maternal milk, which are lost over the first months of life. Thereafter, seroprevalence remains negligible until 3 years of age after which the seroconversion rate progressively increases until adulthood (Calcedo et al [@CR37]; Li et al [@CR122]).

Human CD8^+^ T-cell mediated immune responses are involved in AAV hepatotoxicity and were initially encountered during the first haemophilia B trial (Manno et al [@CR135]). Capsid epitopes, presented via the major histocompatibility complex I (MHC1), were shown to drive expansion of a pre-existing pool of CD8^+^ memory T cells acquired during a previous co-infection of wild type AAV and helper virus (adenovirus or herpes virus for example). This response was dose-dependent (Mingozzi and High [@CR149]) and could be stimulated by alternate capsids (Mingozzi et al [@CR150]).

Hepatic tolerogenic properties involve the proliferation of a specific T cell subset, CD4^+^CD25^+^FoxP3^+^ Treg cells (Cooper et al [@CR57]) interacting with Kupffer cells (Breous et al [@CR26]). Expansion of these cells suppresses cytotoxic immunity against AAV-transduced hepatocytes and induces immunotolerance, e.g. after neonatal injection (Shi et al [@CR199]). Regulatory tolerance requires continuous antigen presentation and has been successfully induced with transgenic proteins (Shi et al [@CR199]; Perrin et al [@CR177]). In contrast, capsid proteins are rapidly eliminated in the proteasome (Berry and Asokan [@CR17]) and therefore very unlikely to induce tolerance.

Various approaches aim to overcome these unwanted immune responses in order either to treat seropositive patients or to prevent sensitisation against the AAV capsid, which would allow reinjection in the future. Capsid modification targeting specific epitopes can evade host immunity (Tseng and Agbandje-McKenna [@CR215]). Any strategy optimising the transduction of the target organ such as optimised expression cassette design, or capsid modifications will in turn decrease the amount of vector required for a similar effect. The decrease in vector dose will further reduce the immune response (Mingozzi and High [@CR148]). Various protocols involving transient immunosuppression have been proposed in large animal models and humans. These include plasmapheresis (Monteilhet et al [@CR156]; Chicoine et al [@CR49]), monoclonal antiCD20 antibody (rituximab) (Mingozzi et al [@CR152]; Corti et al [@CR59]), non-depleting antiCD4 antibody (McIntosh et al [@CR142]), sirolimus (Corti et al [@CR59]), cyclosporine A (McIntosh et al [@CR142]; Mingozzi et al [@CR151]), tacrolimus with mycophenolate mofetil (Chicoine et al [@CR49]), proteasome inhibitors, e.g. bortezomib (Monahan et al [@CR154]) and corticosteroids (Flanigan et al [@CR79]; Chicoine et al [@CR49]; Nathwani et al [@CR165]). One currently controversial strategy to blunt anti-capsid immune responses, is to co-inject "full" AAV vectors and "empty" capsids as decoys, in an attempt to competitively bind existing antibodies (Tse et al [@CR214]).

Optimised targeting {#Sec16}
-------------------

The ideal AAV vector would exclusively transduce the desired target cells. This would limit unwanted immune responses, avoid ectopic transgene expression and further reduce the already low risk of germline transmission. Extensive capsid-focused research based on high-throughput in vitro and in vivo screening of "libraries" of new capsid variants is ongoing in order to optimise vectors for specific applications. These "accelerated evolution" libraries are generated using strategies such as error-prone PCR (Kotterman and Schaffer [@CR118]; Deverman et al [@CR67]) and "capsid shuffling" with random cut-paste sequences of wild type *cap* genes (Kay [@CR111]; Louis Jeune et al [@CR127]; Choudhury et al [@CR51]). This approach is paying off by generating re-engineered AAV variants with increased transduction efficiency in primary human hepatocytes (Lisowski et al [@CR125]).

Germline transmission {#Sec17}
---------------------

The risk for this phenomenon is difficult to quantify. Insertion of AAV sequences into the genome of a gamete could potentially interfere with normal foetal development or promote tumorigenicity in the progeny. So far adult patients enrolled in AAV trials with systemic delivery have been required to use contraception. Vector sequences have been detected transiently in semen of treated patients in AAV2 (Manno et al [@CR135]) or AAV8 (Nathwani et al [@CR165]) trials with the latest clearance of the vector observed at 12 weeks post-injection, quicker in younger men, but not in an AAV5 trial (D'Avola et al [@CR66]). Vector was observed in seminal fluid but not in motile sperm and spermatogonia aligned with previous studies (Arruda et al [@CR7]; Couto et al [@CR61]).

Suboptimal animal models {#Sec18}
------------------------

The following examples demonstrate why animal experiments provide limited value for predicting effects in human trials:T-cell mediated cytotoxicity observed in the first haemophilia B trial was not predicted by experiments in mice, dogs or non-human primates (Pien et al [@CR180]). Unlike research animals, humans are exposed to wild type AAV infections generating anti-AAV memory T cells, which are reactivated at the time of vector exposure (Mingozzi et al [@CR150]).An over 80% rate of HCC was observed in a mouse model of methylmalonic acidaemia injected neonatally with AAV2/8. Integration occurred in the *Rian* hotspot, a rodent-specific locus absent in other vertebrate genomes (Chandler et al [@CR45]).The patterns of liver transgene expression in the hepatic lobule varies among different species. For example, using the AAV8 capsid, transgene expression is predominantly pericentral in mice and dogs and periportal in non-human primates (Fig. [4](#Fig4){ref-type="fig"}) (Bell et al [@CR14]). This is of particular importance for liver diseases where metabolic zonation underpins that certain metabolic functions occur predominantly in certain areas of the liver lobule, which is the functional unit of the liver. For example, the urea cycle activity mostly takes place in periportal hepatocytes (Gebhardt and Matz-Soja [@CR84]). To achieve adequate control of severe hyperammonaemia in the OTCD mouse model, therefore, requires a much higher than expected dose of AAV2/8 vector carrying OTC transgene, which might be explained by the non-physiological pattern of liver transduction (Cunningham et al [@CR64]). Thus, it is difficult to reliably extrapolate vector doses for human translation from studies in mice in liver diseases with metabolic zonation like OTCD.AAV2/8 vectors are capable of transducing 100% hepatocytes in adult mice (Cunningham et al [@CR63]), but data from human trials in haemophilia B have shown an increase in plasma FIX only 2 to 8% (Nienhuis et al [@CR169]), suggesting much less efficient AAV2/8-mediated hepatocyte transduction in humans. Interestingly, most studies in a chimeric FRG (*Fah* ^*−/−*^ */Rag2* ^*−/−*^ */Il2rg* ^*−/−*^) mouse-human liver model (Lisowski et al [@CR125]; Wang et al [@CR222]; Vercauteren et al [@CR217]) showed that AAV3B and AAV3B-derived vectors (AAV3-ST, AAV-LK03) are able to transduce human hepatocytes approximately 10 times more efficiently than AAV2/8 whilst transduction of murine hepatocytes is minimal (Lisowski et al [@CR125]). Fig. 4Species-related differences in transduction of the hepatic lobule by AAV vector compared with metabolic zonation for ammonia clearance: example with AAV2/8 vector

The FRG mouse has a combination of tyrosinaemia type I and immunodeficiency phenotypes and is an attractive model to study human hepatocytes in vivo with the intention of overcoming limitations due to species-specificity (Azuma et al [@CR9]). Human *Fah* ^*+/+*^ hepatocytes have a selective growth advantage relative to the *Fah*-deficient native mouse hepatocytes allowing human cell engraftment up to 90% of the liver mass (Azuma et al [@CR9]). Moreover, this model can address disease-specific questions if engrafted with hepatocytes from patients with liver specific disorders. Recently, the even more complex FRGN (*Fah* ^*−/−*^ */Rag2* ^*−/−*^ */Il2rg* ^*−/−*^ */NOD*) mouse model has been described in which FRG mice, developed in a non-obese diabetic (NOD) mouse strain, are simultaneously co-transplanted with human hepatocytes and human haematopoietic stem cells (Wilson et al [@CR225]).

Limited capacity of AAV vectors {#Sec19}
-------------------------------

The single-stranded AAV vector can accommodate a transgene cassette of approximately 4.6 to 5 kb (Hirsch et al [@CR99]). This capacity is reduced by half (2.3 kb) in self-complementary (i.e double-stranded) vectors. This is a major limitation compared to non-viral or other common viral vectors like lentiviral/retroviral vectors (up to at least 14 kb (Counsell et al [@CR60])) or helper-dependent adenoviruses (up to at least 38.9 kb (Suzuki et al [@CR206])). To deliver oversized transgenes, several approaches have been developed. Designing mini-promoters or mini-genes of interest can be successful (Yan et al [@CR230]). Alternatively, dual AAV co-transduction has been successfully tested either with split AAV or fragment AAV (Hirsch et al [@CR99]). Split AAVs use the inherent tendency for intermolecular genome association observed with AAV genomes via either homologous recombination (HR) or non-homologous end joining (NHEJ) to produce concatemers. The overlapping approach uses vectors A and B, which display a homology sequence to promote intermolecular homologous recombination (Duan et al [@CR72]; Koo et al [@CR117]). In the trans-splicing approach, two splice sites in 3′ cDNA of vector A and 5′ cDNA of vector B are recognised in concatemerized provirus to generate the single DNA molecule of the oversized gene of interest (Duan et al [@CR72]). A combination of the two approaches is known as the hybrid trans-splicing technique (Trapani et al [@CR213]). In fragment AAV, the transgene is not entirely encapsidated but only fragments of different size, which can recombine on overlapping regions (Hirsch et al [@CR99]). A limitation common to these approaches is reduced functional transduction efficiency.

Limited manufacturing capability {#Sec20}
--------------------------------

For the last couple of years, the rise in demand for good-manufacturing practice (GMP) AAV vectors for preclinical and clinical studies has created a bottleneck, delaying a number of projects. The industry is progressively taking up the gauntlet and developing improved and innovative methods for vector production in larger bioreactors with optimised reagents, purification techniques and packaging cell lines (Clement and Grieger [@CR55]; Grieger et al [@CR89]).

Gene therapy requires an innovative economic model for success in modern healthcare {#Sec21}
-----------------------------------------------------------------------------------

Patients with inherited metabolic disorders individually impose a much heavier financial burden on the healthcare system compared to the average person. For example, the lifetime cost for methylmalonic/propionic acidaemias and Gaucher disease is \$1.5 and 5 million, respectively (Li et al [@CR123]; Orkin and Reilly [@CR175]). Gene therapy has the potential to achieve substantial savings. For example, a haemophilia B trial has shown that single injection of the gene therapy product in a cohort of ten patients can save more than \$2.5 million over three years for the healthcare system in the UK (Nathwani et al [@CR165]).

It is likely that to recover the investment in product development, companies will need pricing gene therapy treatments ambitiously when their products reach market. However, the cost of treatment will need to be affordable for public healthcare systems. The first gene therapy product approved by the European Medicines Agency (EMA), Glybera®, is marketed by Uniqure. This drug has been in development for 8 years, with the initial developer going bankrupt and a currently proposed market cost of \$1.2 million per patient (Bryant et al [@CR32]). GlaxoSmithKline's Strimvelis® is the second gene therapy product to reach the market and was approved by the EMA in 2016. This gene therapy product, which targets ADA-SCID has been in development for over 16 years and the proposed cost is \$665,000 per patient (Hoggatt [@CR100]; Schimmer and Breazzano [@CR196]).

Over the last 20 years, greater than \$4.3 billion have been spent on development of gene therapy technology and return on this investment is still awaited (Ledley et al [@CR121]). Although most of the gene therapy programmes remain in the early stages of development, healthcare economists are generating models to cost treatments, which might provide lifelong cures. A pay-for-performance system has been proposed with yearly-capped annuity paid to the pharmaceutical company if criteria of a metabolic control of the disease are met (Touchot and Flume [@CR212]). These criteria might reflect cost-effectiveness and not only cost-saving. This approach values the gain in quality of life estimated by quality-adjusted life years (QALY) analysis, which includes many parameters such as lifespan and ability to work (Orkin and Reilly [@CR175]). Vouchers systems with longer financial incentives might be another option (Schimmer and Breazzano [@CR196]).

In parallel, the regulatory framework is evolving with the progress of technology and the increasing experience being gathered from human trials. The Food and Drug Administration (FDA) and the EMA have published recommendations for gene therapy products (Narayanan et al [@CR162]). The need for shorter and less expensive paths to clinical trials and conditional approval relying more on human data for safety and efficacy has now been recognised, as exemplified by the FDA's Breakthrough Therapies programme and the EMA's Adaptive Pathways and Priority Medicines (PRIME) schemes which were launched in 2012, 2014 and 2016, respectively (Mullard [@CR160]). These more flexible pathways will need to be agreed by government funding bodies (Macaulay [@CR130]).

Considerations for paediatric application {#Sec22}
=========================================

Paediatric administration of gene therapy has several theoretical advantages (McKay et al [@CR143]). These include prevention of early death or irreversible neurological sequellae, transduction of stem/progenitor cells and possible avoidance of immune response as neonates have an immature immune system, while infants and children have lower rates of pre-existing anti-AAV immunity. The potential for even earlier gene therapy intervention has been explored in late gestation foetal macaques by intrahepatic injection of *sc*AAV2/8 and *sc*AAV2/5 vectors. Plasma human FIX levels of 8--112% were observed during a median follow-up period of 14 months without evidence hotspot integration and HCC (Mattar et al [@CR136]).

There is a theoretical risk, however, of increased tumorigenicity in the developing liver as observed in experiments performed in neonatal mice (Donsante et al [@CR71]; Chandler et al [@CR45]). A further challenge in the paediatric liver is the likely progressive loss of vector genomes over time in concert with hepatocellular proliferation. More than 90% of the AAV-delivered transgene cassettes exists as non-integrated episomes (Cunningham et al [@CR63]). The human liver weight doubles at 4 months, 16 months, 6 years and 12 years of age, which means that the adult liver is 16 times heavier than the neonatal liver (Coppoletta and Wolbach [@CR58]; Sunderman and Boerner [@CR204]). Therefore, it is unlikely that a neonatal injection will be sufficient to provide lifelong correction of the phenotype in metabolic liver diseases, with reinjection during the phase of rapid liver growth likely to be necessary.

An alternative approach to reinjection could be the use of integrating vectors and or locus-specific genome engineering. Sangamo Therapeutics Inc. is developing tools for transgene integration into the albumin locus and uses zinc finger nucleases coupled with AAV technology. Other genome editing tools have been successfully tested with AAV vectors in a neonatal OTC deficiency mouse model. In these experiments, two AAV vectors were injected simultaneously, one of which encoded the transgene and the other the enzymatic system for integration or site specific cutting by Piggybac transposase (Cunningham et al [@CR65]) and CRISPR-Cas9 (Yang et al [@CR233]), respectively.

Muscle-directed gene therapy for liver monogenic disorders {#Sec23}
----------------------------------------------------------

Muscle-directed gene therapy has been developed for liver monogenic disorders with secreted protein such as haemophilia A and B and α1-antitrypsin deficiency. Intramuscular injections might circumvent some caveats observed with systemic injection, the common route of delivery for liver-targeted gene therapy: limited biodistribution with reduced risk of germline transmission, minimal exposure to circulating neutralising antibodies, reduced dose of vector for a similar effect.

A proof of concept using AAV2 vectors in mice (Herzog et al [@CR96]) and dogs (Herzog et al [@CR97]) affected by haemophilia B paved the way for a clinical trial (Kay et al [@CR112]; Manno et al [@CR134]), which showed a safe profile with long-standing expression in some patients (Jiang et al, [@CR104], [@CR105]; Buchlis et al [@CR33]) but only a mild increase in plasma factor IX around 1% (Manno et al [@CR134]). Depending on the dose considered, dozens to hundreds of intramuscular injections are necessary, which makes this route particularly impractical. For instance, Manno et al administered between 10 to 90 injections per patients in lower limbs (Manno et al [@CR134]). Similarly, a proof of concept in mice with haemophilia A has been reported (Mah et al [@CR132]).

Three AAV-mediated clinical trials have been conducted for α1-antitrypsin deficiency. In this disorder, a plasma level of wild-type (M) α1-antitrypsin above 11 μM is considered reducing the risk of developing emphysema. A first trial based on an AAV2 capsid showed an acceptable safety profile with mild local reactions at the site of intramuscular injection (redness, tenderness, bruising) and a seroconversion against AAV2. Unfortunately, only one out of 12 patients demonstrated a minimal increase of plasma M α1-antitrypsin at 82 nM (Flotte et al [@CR80]; Brantly et al [@CR24]). Two other trials (phase I then phase II) were conducted with a vector based on AAV1 capsid known for its better muscle transduction compared to AAV2 (Flotte et al [@CR81]). In both trials, minor side effects and a seroconversion against AAV1 were observed (Brantly et al [@CR25]; Flotte et al [@CR81]). A moderate infiltration of reactive T lymphocytes in muscle biopsies was noticed (Flotte et al [@CR81]). Plasma levels of M α1-antitrypsin were still mild, although improving in the latest trial due to higher doses injected (412 to 694 nM in the highest dose group) but far from the targeted protective level of 11 μM (Flotte et al [@CR81]).

Conclusion {#Sec24}
==========

Over the last decade, major discoveries in the understanding of viral vector biology have generated promising results in pioneering clinical trials for haemophilia B using AAV vectors. This has paved the way for a wider development of AAV-mediated gene therapy for monogenic liver disorders. Although several clinical, manufacturing and economic challenges remain, this approach to treatment for severely debilitating diseases generated widespread enthusiasm shared by clinicians, researchers and investors alike. Gene transfer technologies are reaching an exciting threshold of efficacy and promise to revolutionise the management of many currently untreatable diseases.
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